BioSpace News Archive

Business

United Therapeutics Corporation Reports Third Quarter 2018 Financial Results

United Therapeutics Corporation today announced its financial results for the quarter ended September 30, 2018.

October 31, 2018
·
14 min read
Pharm Country

Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

Anticipates projected pro forma annual net revenue of between $80 and $90 million.

October 31, 2018
·
9 min read
Business

Acorda Provides Financial and Pipeline Update for Third Quarter 2018

AMPYRA® (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million

October 31, 2018
·
14 min read
Business

LivaNova Reports Third Quarter 2018 Results

LivaNova PLC today reported results for the quarter ended September 30, 2018.

October 31, 2018
·
30 min read
Pharm Country

Fifth Season Financial Presents Key Findings to Address and Prevent Financial Toxicity

Industry Experts Offer Insight for Individuals Diagnosed with Late-Stage Illness

October 31, 2018
·
5 min read
Business

Ophthotech Reports Third Quarter 2018 Financial and Operating Results

Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today

October 31, 2018
·
11 min read
Business

Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)

Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease

October 31, 2018
·
6 min read
Deals

Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4

- Ophthotech Gains HtrA1 Inhibitors to Treat Age-related Retinal Diseases -

October 31, 2018
·
6 min read
Drug Development

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)

Pimavanserin met primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to placebo (p=0.039).

October 31, 2018
·
9 min read
Deals

Conduent to Acquire Health Solutions Plus, Enhancing Core Administration Processing Capabilities

Conduent Incorporated announced it has reached a definitive agreement to acquire Health Solutions Plus (HSP)

October 31, 2018
·
4 min read